MiR-330-5p targets OY-TES-1 to inhibit the migration of glioblastoma

LIANG Guo; ZHAO Zhen-kai; ZENG Zhao-yue; ZHANG Qing-mei; NONG Wei-xia; XIE Xiao-xun; LI Xi-sheng

doi:10.11659/jjssx.03E024085

您当前的位置：

首页 >

文章列表页 >

MiR-330-5p targets OY-TES-1 to inhibit the migration of glioblastoma

Basic Research | 更新时间：2025-01-21

- MiR-330-5p targets OY-TES-1 to inhibit the migration of glioblastoma
- JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY Vol. 34, Issue 2, Pages: 98-103(2025)
- 作者机构：
  
  1.广西医科大学基础医学院组织学与胚胎学教研室，广西南宁 530021
  2.广西医学科学院·广西壮族自治区人民医院颅脑肿瘤创伤功能神经外科，广西南宁 530021
- 作者简介：
- 基金信息：
- DOI：10.11659/jjssx.03E024085
  CLC： R392.12
- Published：25 February 2025，
  
  Received：16 March 2024，
- 稿件说明：
移动端阅览
LIANG GUO, ZHAO ZHEN-KAI, ZENG ZHAO-YUE, et al. MiR-330-5p targets OY-TES-1 to inhibit the migration of glioblastoma. [J]. Journal of regional anatomy and operative surgery, 2025, 34(2): 98-103.
DOI：

LIANG GUO, ZHAO ZHEN-KAI, ZENG ZHAO-YUE, et al. MiR-330-5p targets OY-TES-1 to inhibit the migration of glioblastoma. [J]. Journal of regional anatomy and operative surgery, 2025, 34(2): 98-103. DOI： 10.11659/jjssx.03E024085.

摘要

目的

探究胶质母细胞瘤中miR-330-5p对OY-TES-1的靶向调控关系以及miR-330-5p/OY-TES-1轴对胶质母细胞瘤的迁移能力的影响。

方法

生物信息学分析胶质母细胞瘤患者中miR-330-5p的表达水平及其对患者预后生存的影响。将胶质母细胞瘤细胞U251分为miR-330-5p minics组、minics-NC组和miR-330-5p+OY-TES-1过表达组（miR-330-5p minics+pcDNA3.1-OY-TES-1）。使用双荧光素酶报告基因实验检测miR-330-5p对OY-TES-1 3'UTR区域活性的影响；使用qRT-PCR检测OY-TES-1 mRNA表达；采用Transwell迁移实验检测miR-330-5p/OY-TES-1轴对胶质母细胞瘤细胞迁移能力的影响。

结果

胶质母细胞瘤组织中miR-330-5p的表达明显低于非瘤脑组织和低级别胶质瘤组织(

0.05)。高表达miR-330-5p的胶质母细胞瘤患者生存期显著长于低表达miR-330-5p患者(

0.05)。过表达miR-330-5p后OY-TES-1 3'UTR区域活性下降

0.05)。与minics-NC组相比，miR-330-5p minics组U251和U87MG细胞中OY-TES-1 mRNA表达水平显著降低(

0.01)。与minics-NC组相比，miR-330-5p minics组及miR-330-5p+OY-TES-1过表达组迁移细胞数显著减少（

0.05）；与miR-330-5p minics组相比，miR-330-5p+OY-TES-1过表达组迁移细胞数显著增加（

0.01）。

结论

miR-330-5p靶向调控OY-TES-1抑制胶质母细胞瘤的迁移。

Abstract

Objective

To explore the targeted regulatory relationship of miR-330-5p on OY-TES-1 in glioblastoma and the effect of miR-330-5p/OY-TES-1 axis on the migration ability of glioblastoma.

Methods

Bioinformatics analysis was performed to analyze the expression level of miR-330-5p in patients with glioblastoma and its influence on prognosis and survival of patients. The glioblastoma cells U251 were divided into miR-330-5p minics group， minics-NC group， and miR-330-5p+OY-TES-1 overexpression group （miR-330-5p minics+pcDNA3.1-OY-TES-1）. The effect of miR-330-5p on the activity of OY-TES-1 3'UTR region was detected by double luciferase reporter gene experiment. The expression of OY-TES-1 mRNA was detected by qRT-PCR. The effect of miR-330-5p/OY-TES-1 axis on the migration ability of glioblastoma cells was detected by Transwell migration assay.

Results

The expression of miR-330-5p in glioblastoma tissue was significant

ly lower than those in non-tumor brain tissue and low-grade glioma tissue （

0.05）. The survival time of glioblastoma patients with high expression of miR-330-5p was significantly longer than that of patients with low expression of miR-330-5p （

0.05）. After overexpression of miR-330-5p， the activity of OY-TES-1 3'UTR region was decreased （

0.05）. Compared with minics-NC group， the expression levels of OY-TES-1 mRNA of U251 and U87MG cells in miR-330-5p minics group were significantly decreased （

0.01）. Compared with minics-NC group， the numbers of migrating cells in miR-330-5p minics group and miR-330-5p+OY-TES-1 overexpression group were significantly decreased （

0.05）. Compared with miR-330-5p minics group， the number of migrating cells in miR-330-5p+OY-TES-1 overexpression group was significantly increased （

0.01）.

Conclusion

MiR-330-5p targets OY-TES-1 to inhibit the migration of glioblastoma.

关键词

miR-330-5pOY-TES-1胶质母细胞瘤细胞迁移

Keywords

miR-330-5pOY-TES-1glioblastomacell migration

references

Kohler BA，Ward E，McCarthy BJ，et al.Annual report to the nation on the status of cancer，1975-2007，featuring tumors of the brain and other nervous system［J］.J Natl Cancer Inst，2011，103（9）：714-736.doi：10.1093/jnci/djr077http://dx.doi.org/10.1093/jnci/djr077.

Ostrom QT，Gittleman H，Truitt G，et al.CBTRUS statistical report：primary brain and other central nervous system tumors diagnosed in the united states in 2011-2015［J］.Neuro Oncol，2018，20（suppl_4）：iv1-iv86.doi：10.1093/neuonc/noy131http://dx.doi.org/10.1093/neuonc/noy131.

Julka PK，Sharma DN，Mallick S，et al.Postoperative treatment of glioblastoma multiforme with radiation therapy plus concomitant and adjuvant temozolomide ：a mono-institutional experience of 215 patients［J］.J Cancer Res Ther，2013，9（3）：381-386.doi：10.4103/0973-1482.119310http://dx.doi.org/10.4103/0973-1482.119310.

Morgan LL.The epidemiology of glioma in adults：a "state of the science" review［J］.Neuro Oncol，2015，17（4）：623-624.doi：10.1093/neuonc/nou358http://dx.doi.org/10.1093/neuonc/nou358.

Dai L，Liang W，Shi Z，et al.Systematic characterization and biological functions of non-coding RNAs in glioblastoma［J］.Cell Prolif，2023，56（3）：e13375.doi：10.1111/cpr.13375http://dx.doi.org/10.1111/cpr.13375.

Li Y，Xu J，Chen H，et al.Comprehensive analysis of the functional microRNA-mRNA regulatory network identifies miRNA signatures associated with glioma malignant progression［J］.Nucleic Acids Res，2013，41（22）：e203.doi：10.1093/nar/gkt1054http://dx.doi.org/10.1093/nar/gkt1054.

Sumazin P，Yang X，Chiu HS，et al.An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma［J］.Cell，2011，147（2）：370-381.doi：10.1016/j.cell.2011.09.041http://dx.doi.org/10.1016/j.cell.2011.09.041.

Yan C，Kong X，Gong S，et al.Recent advances of the regulation roles of MicroRNA in glioblastoma［J］.Int J Clin Oncol，2020，25（7）：1215-1222.doi：10.1007/s10147-020-01685-yhttp://dx.doi.org/10.1007/s10147-020-01685-y.

Yoo HI，Kim BK，Yoon SK.MicroRNA-330-5p negatively regulates ITGA5 expression in human colorectal cancer［J］.Oncol Rep，2016，36（5）：3023-3029.doi：10.3892/or.2016.5092http://dx.doi.org/10.3892/or.2016.5092.

Tréhoux S，Lahdaoui F，Delpu Y，et al.Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells［J］.Biochim Biophys Acta，2015，1853（10 Pt A）：2392-2403.doi：10.1016/j.bbamcr.2015.05.033http://dx.doi.org/10.1016/j.bbamcr.2015.05.033.

Tammela J，Uenaka A，Ono T，et al.OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer［J］.Int J Oncol，2006，29（4）：903-910.

Fan R，Huang W，Luo B，et al.Cancer testis antigen OY-TES-1：analysis of protein expression in ovarian cancer with tissue microarrays［J］.Eur J Gynaecol Oncol，2015，36（3）：298-303.

Li X，Yan J，Fan R，et al.Serum immunoreactivity of cancer/testis antigen OY-TES-1 and its tissues expression in glioma［J］.Oncol Lett，2017，13（5）：3080-3086.doi：10.3892/ol.2017.5799http://dx.doi.org/10.3892/ol.2017.5799.

Luo B，Yun X，Fan R，et al.Cancer testis antigen OY-TES-1 expression and serum immunogenicity in colorectal cancer：its relationship to clinicopathological parameters［J］.Int J Clin Exp Pathol，2013，6（12）：2835-2845.

范蓉，肖绍文，黄巍，等.肝细胞癌中OY-TES-1基因mRNA的表达［J］.肿瘤防治研究，2010，37（7）：810-812.doi：10.3971/j.issn. 1000-8578.2010.07.020http://dx.doi.org/10.3971/j.issn.1000-8578.2010.07.020.

Pierscianek D，Ahmadipour Y，Oppong MD，et al.Blood-based biomarkers in high grade gliomas：a systematic review［J］.Mol Neurobiol，2019，56（9）：6071-6079.doi：10.1007/s12035-019-1509-2http://dx.doi.org/10.1007/s12035-019-1509-2.

Young JS，Dayani F，Morshed RA，et al.Immunotherapy for high-grade gliomas：a clinical update and practical considerations for neurosurgeons［J］.World Neurosurg，2019，124：397-409.doi：10.1016/j.wneu.2018.12.222http://dx.doi.org/10.1016/j.wneu.2018.12.222.

Dehaini H，Awada H，El-Yazbi A，et al.MicroRNAs as potential pharmaco-targets in ischemia-reperfusion injury compounded by diabetes［J］.Cells，2019，8（2）：152.doi：10.3390/cells8020152http://dx.doi.org/10.3390/cells8020152.

Si W，Shen J，Zheng H，et al.The role and mechanisms of action of microRNAs in cancer drug resistance［J］.Clin Epigenetics，2019，11（1）：25.doi：10.1186/s13148-018-0587-8http://dx.doi.org/10.1186/s13148-018-0587-8.

Chen R，Wang G，Zheng Y，et al.Drug resistance-related microRNAs in osteosarcoma：translating basic evidence into therapeutic strategies［J］.J Cell Mol Med，2019，23（4）：2280-2292.doi：10.1111/jcmm. 14064http://dx.doi.org/10.1111/jcmm.14064.

Qi Y，Wang X，Kong X，et al.Expression signatures and roles of microRNAs in inflammatory breast cancer［J］.Cancer Cell Int，2019，19：23.doi：10.1186/s12935-018-0709-6http://dx.doi.org/10.1186/s12935-018-0709-6.

Sun G，Cao Y，Shi L，et al.Overexpressed miRNA-137 inhibits human glioma cells growth by targeting Rac1［J］.Cancer Biother Radiopharm，2013，28（4）：327-334.doi：10.1089/cbr.2012.1380http://dx.doi.org/10.1089/cbr.2012.1380.

Cavallo F，De Giovanni C，Nanni P，et al.2011：the immune hallmarks of cancer［J］.Cancer Immunol Immunother，2011，60（3）：319-326.doi：10.1007/s00262-010-0968-0http://dx.doi.org/10.1007/s00262-010-0968-0.

Pang Y， Young CY， Yuan H. MicroRNAs and prostate cancer［J］. Acta Biochim Biophys Sin （Shanghai），2010，42（6）：363-369. doi：10.1093/abbs/gmq038http://dx.doi.org/10.1093/abbs/gmq038.

Wang MH，Liu ZH，Zhang HX，et al.Hsa_circRNA_000166 accelerates breast cancer progression via the regulation of the miR-326/ELK1 and miR-330-5p/ELK1 axes［J］.Ann Med，2024，56（1）：2424515.doi：10.1080/07853890.2024.2424515http://dx.doi.org/10.1080/07853890.2024.2424515.

Chen L，Yang X，Zhao J，et al.Circ_0008532 promotes bladder cancer progression by regulation of the miR-155-5p/miR-330-5p/MTGR1 axis［J］.J Exp Clin Cancer Res，2020，39（1）：94.doi：10.1186/s13046-020-01592-0http://dx.doi.org/10.1186/s13046-020-01592-0.

Xu S，Lei SL，Liu KJ，et al.circSFMBT1 promotes pancreatic cancer growth and metastasis via targeting miR-330-5p/PAK1 axis［J］.Cancer Gene Ther，2021，28（3-4）：234-249.doi：10.1038/s41417-020-00215-2http://dx.doi.org/10.1038/s41417-020-00215-2.

Cheng H，Wang N，Tian J，et al.Circular RNA Circ_0025033 promotes the evolvement of ovarian cancer through the regulation of miR-330-5p/KLK4 Axis［J］.Cancer Manag Res，2020，12：2753-2765.doi：10.2147/cmar.S241372http://dx.doi.org/10.2147/cmar.S241372.

Scanlan MJ，Gure AO，Jungbluth AA，et al.Cancer/testis antigens：an expanding family of targets for cancer immunotherapy［J］.Immunol Rev，2002，188：22-32.doi：10.1034/j.1600-065x.2002.18803.xhttp://dx.doi.org/10.1034/j.1600-065x.2002.18803.x.

Saproo S，Sarkar SS，Gupta E，et al.MiR-330-5p and miR-1270 target essential components of RNA polymerase I transcription and exhibit a novel tumor suppressor role in lung adenocarcinoma［J］.Cancer Gene Ther，2023，30（2）：288-301.doi：10.1038/s41417-022-00544-4http://dx.doi.org/10.1038/s41417-022-00544-4.

Liu J，Yue K，Yang J，et al.miR-330-5p suppress cell growth and invasion via disrupting HSF4-mediated MACC1/STAT3 pathway in colorectal cancer［J］.Front Biosci （Landmark Ed），2024，29（2）：53.doi：10.31083/j.fbl2902053http://dx.doi.org/10.31083/j.fbl2902053.

Kim BK，Yoo HI，Choi K，et al.miR-330-5p inhibits proliferation and migration of keratinocytes by targeting Pdia3 expression［J］.FEBS J，2015，282（24）：4692-4702.doi：10.1111/febs.13523http://dx.doi.org/10.1111/febs.13523.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Rosmarinic acid inhibits the proliferation and migration of laryngeal carcinoma cells through the PI3K/AKT/mTOR signaling pathway

Daidzein targeting MMP12 against oral squamous cell carcinoma

Effects of miR-483 targeting DLC1 on the proliferation,migration and invasion of triple negative breast cancer cells

Related Author

YAN Qing

YANG Hua-rong

WANG Na-na

LYU Hong-juan

ZHANG Xuan

LI Li-heng

MENG Yuan-yuan

ZHAO Ting-ting

Related Institution

Department of Rhinolaryngology， Affiliated Hospital of Yan'an University

Department of Oral and Maxillofacial Surgery， First Hospital Affiliated to Hebei North University

Department of Breast and Nail Surgery,Affiliated Zhongshan Hospital of Dalian University

⁰